Raymond James & Associates Veracyte, Inc. Transaction History

Raymond James & Associates

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$15.45 - $29.52 $1.27 Million - $2.43 Million	82,230 New	82,230 $1.64 Million
Q1 2020 Apr 21, 2020	SELL	$16.13 - $30.17 $190,592 - $356,488	-11,816 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$20.78 - $29.99 $154,977 - $223,665	-7,458 Reduced 38.69%	11,816 $330,000
Q3 2019 Nov 07, 2019	BUY	$23.87 - $30.93 $87,053 - $112,801	3,647 Added 23.34%	19,274 $463,000
Q2 2019 Aug 06, 2019	BUY	$22.1 - $28.56 $345,356 - $446,307	15,627 New	15,627 $446,000
Q2 2018 Aug 14, 2018	SELL	$5.39 - $9.66 $134,750 - $241,500	-25,000 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$5.44 - $6.97 $136,000 - $174,250	25,000 New	25,000 $139,000

307

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.